ANI Pharma (ANIP) Misses Q4 EPS by 10c, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020
February 27, 2020 8:30 AM ESTBAUDETTE, Minn., Feb. 27, 2020 /PRNewswire/ --
For the full year ended December 31, 2019:
Record net revenues of $206.5 million, an increase of 2.5% versus 2018 GAAP net income of $6.1 million and diluted GAAP earnings per share of $0.50 Adjusted non-GAAP EBITDA of $83.2 million Adjusted non-GAAP diluted earnings per share of $5.06For the fourth quarter 2019:
Net revenues of $48.0 million versus $57.1 million in 2018 GAAP net loss of $4.8 million and diluted GAAP loss per share of $0.41 Adjusted non-GAAP EBITDA of $17.4 million... More